Navigation Links
Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer
Date:1/14/2009

rt an optimal therapeutic dose level of 50 kBq/kg as selected for use in the global phase III ALSYMPCA trial (see below for further details).

Furthermore, the successful completion of the phase II program also supports Algeta's strategy for targeting Alpharadin at patients with metastatic HRPC who are unsuitable or who have failed docetaxel chemotherapy and for first-line use in combination with docetaxel. A combination study is in preparation, which if successful will enable Algeta to market Alpharadin, either alone or in combination with docetaxel, to approximately 85% of the global HRPC market.

Algeta's President and CEO, Dr. Thomas Ramdahl, said: "The completion of the phase II program is an important milestone for Algeta that gives us great confidence in the potential of Alpharadin as a new, safe and effective treatment for metastatic prostate cancer. The program has demonstrated not only that Alpharadin can improve patient quality of life by successfully treating the painful and debilitating bone metastases arising from the primary cancer, but also that it has a proven survival benefit for patients. We believe there is not a single cancer therapeutic available today offering these patients such clinical benefits, let alone one which is so readily tolerated. We remain confident that the phase III clinical program will confirm these impressive results and support a strong case for regulatory approval in due course."

Dr Chris Parker, a prostate cancer specialist based at the Institute of Cancer Research and the Royal Marsden Hospital in Sutton, UK, and the study's principal investigator, said: "The clinical results generated so far for Alpharadin in treating metastatic prostate cancer are highly encouraging and offer patients the possibility of an effective treatment that both prolongs life while also maintaining quality of life. In addition, the results announced today further emphasize the remark
'/>"/>

SOURCE Algeta
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
2. MicroPhage Successfully Completes Beta Trial for Rapid MRSA Test
3. Jazz Pharmaceuticals, Inc. Completes Enrollment in Second of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
4. Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment
5. Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
6. Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma
7. Essentialis Completes Patient Enrollment in Phase 2 Trial of DDCR for Treatment of Dyslipidemia
8. Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
9. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
10. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
11. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , October 22, 2014 Investor-Edge ... Inc. (NASDAQ: FOLD ), Progenics Pharmaceuticals Inc. ... THLD ), Idera Pharmaceuticals Inc. (NASDAQ: ... Free research on these five companies can be accessed ... 21, 2014, the NASDAQ Composite ended at 4,419.48, up ...
(Date:10/22/2014)... Calif. , Oct. 22, 2014  Paper ... products, has developed APLS ® Body Guard ... minimizes the spread of bacteria and virus while ... APLS Body Guard Bio features a rugged, external ... edges that create a leak-proof inner chamber that ...
(Date:10/22/2014)... , October 22, 2014 ... ), a clinical-stage pharmaceutical company focused on ... reported positive top-line clinical results from its Phase ... oral insulin capsules, to treat type 1 diabetes. The ... States under a U.S. Food and ...
Breaking Medicine Technology:Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 2Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 4Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 5New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4
... 2010 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. ("China-Biotics" or "the ... developer, manufacturer and distributor of probiotics products in ... Company,s research and development department presented at the ... Equipment seminar in Hangzhou, China on November 21st. ...
... (OTC Bulletin Board: GOVX ) (the "Company"), an ... Immunodeficiency Virus), has appointed David A. Dodd as Chairman of ... Hildebrand is stepping down as Chairman and will remain on ... a consultant to the Company. Mr. Dodd, age ...
Cached Medicine Technology:China-Biotics Attended National Probiotics Seminar 2China-Biotics Attended National Probiotics Seminar 3David A. Dodd Appointed Chairman of the Board of GeoVax Labs 2David A. Dodd Appointed Chairman of the Board of GeoVax Labs 3David A. Dodd Appointed Chairman of the Board of GeoVax Labs 4
(Date:10/25/2014)... HealthDay Reporter FRIDAY, Oct. ... cold sores -- herpes simplex -- might increase the risk ... In fact, being a carrier of certain antibodies to the ... found. "The identification of a treatable cause [herpes ... said lead researcher Dr. Hugo Lovheim, an associate professor in ...
(Date:10/25/2014)... (HealthDay News) -- A large influx of international aid ... avoid tens of thousands of deaths from the widening ... Using a specially designed mathematical model, the ... in just one densely populated county of hard-hit Liberia ... Monrovia. The researchers said that if international aid ...
(Date:10/25/2014)... FRIDAY, Oct. 24, 2014 (HealthDay News) -- October,s shorter, ... as seasonal affective disorder, according to an expert. ... SAD, may feel overly tired, lack motivation and even ... SAD can lead to suicide, said Dr. Angelos Halaris, ... neurosciences at Loyola University Chicago Stitch School of Medicine. ...
(Date:10/22/2014)... On October 22, CBS will air an ... both fictional and real. The Charles E Holman ... to advocacy and philanthropy in the battle against Morgellons ... to impart truth and clarity about this misunderstood and ... misconceptions about Morgellons Disease (MD) and most ...
(Date:10/22/2014)... 2014 For Dr. Iris Hunter, a job ... an extension of her life’s mission. Her extensive experience in ... owner of FirstLight HomeCare, make it clear that Hunter’s mission ... that my work makes a difference in the lives of ... so after much research, I felt ready to start on ...
Breaking Medicine News(10 mins):Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 3Health News:Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid Delayed 2Health News:Dark Days Here for Folks With Seasonal Depression 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2
... treatment, study shows , TUESDAY, Jan. 26 (HealthDay News) ... to lower high blood glucose levels caused by corticosteroid ... study has found. , The death rate for septic ... is 60 percent within a short period, according to ...
... CHICAGO , Jan. 26 After a week of trial ... $1-million insurance policy on January 20, 2010 , to settle a ... the physician,s failure to timely diagnose bladder cancer. , In Russell v. ... Carmen Russell and Daniel Russell, Jr. , the wife and ...
... , International Guidelines Ensure Maximum Protection of Children ... Just weeks after the United Nations General Assembly adopted a resolution ... the international community is struggling to provide appropriate care and protection ... Haiti . The Guidelines are the first international document on ...
... NASHVILLE, Tenn. , Jan. 26 Saint ... clinical quality among the top five percent in the nation ... is one of only 269 hospitals that received this distinction ... , The study by HealthGrades, the leading independent healthcare ratings ...
... 26 President Obama will need several props to get ... a box of teabags, a paper shredder, and a new "No ... by taking the 2,074 page Senate health bill and stuffing it ... a 20-page bill in plain, honest English," says Betsy McCaughey ...
... heart defects (CHD) are the most common birth ... births with one third of affected children requiring ... combined with developmental expectations for independence, behavioral self-regulation ... identification of neurobehavioral symptoms in some survivors. A ...
Cached Medicine News:Health News:Intensive Insulin Therapy Won't Boost Septic Shock Survival 2Health News:Romanucci & Blandin, LLC, Reaches $1 Million Settlement in Medical Negligence Lawsuit 2Health News:International Community Calls for Prevention of Further Trauma in Haiti 2Health News:International Community Calls for Prevention of Further Trauma in Haiti 3Health News:Saint Thomas Hospital Ranked Top Five Percent in Nation for the Second Consecutive Year According to Quality Study 2Health News:Props for the President at His State of the Union Address 2Health News:Bypass procedure used during infant heart surgery does not impair later neurological outcomes 2
... CCR Medical's Articulating Tip Laryngoscopes ... in the Industry. The articulating ... by providing an improved view ... and Fiber Optic styles. We ...
German Style MacIntosh Fiber Optic Blade Laryngoscopes...
CCR Medical fiberoptic green system laryngoscope handles., ,OUTSTANDING PERFORMANCE, QUALITY, AND PRICING MAKE OUR FIBEROPTIC SELECTION MOST ECONOMICAL....
CCR Medical fiberoptic green system laryngoscope handles., ,OUTSTANDING PERFORMANCE, QUALITY, AND PRICING MAKE OUR FIBEROPTIC SELECTION MOST ECONOMICAL....
Medicine Products: